The next big Rx-to-OTC switch opportunity in 2017 could be migraine treatments.
(To view the full Category Review, click here.)
“They did switch Imitrex [in Europe],” Laura Mahecha, industry manager healthcare for Kline Group, said, citing concerns of “potential cardiovascular side effects.” Mahecha called the potential of a 2017 migraine switch “low to moderate.”